Influvac Tetra, suspension for injection in pre-filled syringe (influenza vaccine, surface antigen, inactivated) Ireland - English - HPRA (Health Products Regulatory Authority)

influvac tetra, suspension for injection in pre-filled syringe (influenza vaccine, surface antigen, inactivated)

mylan ire healthcare limited - a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/2570/2019, ivr-215) ; a/darwin/9/2021 (h3n2) - like strain (a/darwin/9/2021, ivr-228); b/phuket/3073/2013 -like strain (b/phuket/3073/2013, wild type); b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type) - suspension for injection in pre-filled syringe - 15 microgram(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen

Influvac sub-unit Tetra, suspension for injection in pre-filled syringe 15mcg/0.5ml Malta - English - Medicines Authority

influvac sub-unit tetra, suspension for injection in pre-filled syringe 15mcg/0.5ml

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - influenza vaccine, split virion, inactivated - suspension for injection in pre-filled syringe - influenza vaccine (split virion, inactivated) 15 µg - vaccines

Influvac sub-unit Tetra, suspension for injection in pre-filled syringe Malta - English - Medicines Authority

influvac sub-unit tetra, suspension for injection in pre-filled syringe

viatris healthcare limited damastown industrial park, mulhuddart, dublin 15, dublin , ireland - suspension for injection in pre-filled syringe - influenza vaccine (split virion, inactivated) 15 µg - vaccines

Influvac Tetra, suspension for injection in pre-filled syringe (influenza vaccine, surface antigen, inactivated) Ireland - English - HPRA (Health Products Regulatory Authority)

influvac tetra, suspension for injection in pre-filled syringe (influenza vaccine, surface antigen, inactivated)

viatris healthcare limited - a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/2570/2019, ivr-215) ; a/darwin/9/2021 (h3n2) - like strain (a/darwin/9/2021, ivr-228); b/phuket/3073/2013 -like strain (b/phuket/3073/2013, wild type); b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type) - suspension for injection in pre-filled syringe - influenza vaccines; influenza, inactivated, split virus or surface antigen

Ganfort European Union - English - EMA (European Medicines Agency)

ganfort

allergan pharmaceuticals ireland - bimatoprost, timolol - glaucoma, open-angle, ocular hypertension - ophthalmologicals, - reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Increlex European Union - English - EMA (European Medicines Agency)

increlex

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.

Lopinavir/Ritonavir Mylan European Union - English - EMA (European Medicines Agency)

lopinavir/ritonavir mylan

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

STAY SAFE BALANCE 1.5% glucose 1.25 mmolL calcium peritoneal dialysis solution bag Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

stay safe balance 1.5% glucose 1.25 mmoll calcium peritoneal dialysis solution bag

fresenius medical care malaysia sdn bhd - calcium chloride dihydrate ph. eur.; magnesium chloride hexahydrate pheur; glucose monohydrate, ph eur; sodium chloride (nacl); sodium lactate (50%) -

STAY SAFE BALANCE 2.3% glucose 1.25 mmolL calcium peritoneal dialysis solution bag Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

stay safe balance 2.3% glucose 1.25 mmoll calcium peritoneal dialysis solution bag

fresenius medical care malaysia sdn bhd - magnesium chloride hexahydrate pheur; sodium lactate solution (50%); glucose monohydrate, ph eur; sodium chloride (nacl); calcium chloride dihydrate ph. eur. -

STAY SAFE BALANCE 4.25% glucose 1.25 mmolL calcium peritoneal dialysis solution bag Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

stay safe balance 4.25% glucose 1.25 mmoll calcium peritoneal dialysis solution bag

fresenius medical care malaysia sdn bhd - sodium chloride ph eur; calcium chloride dihydrate ph. eur.; magnesium chloride hexahydrate pheur; glucose monohydrate, ph eur; sodium lactate solution (50%) -